Fisher & Paykel Healthcare Corporation Limited announced at its investor day in Sydney the introduction of the F&P Eson 2 nasal mask for the treatment of obstructive sleep apnea.
The F&P Eson 2 is the first of the next generation of Fisher & Paykel Healthcare’s comfortable and easy-to-use masks and builds on the success of the F&P Eson nasal mask with more than 20 design improvements.
“Our development team has focused on ease of use, to provide sleep professionals and patients confidence at every step from titration through to adherence,” says Lewis Gradon, Fisher & Paykel Healthcare’s senior vice president of products and technology and CEO designate, in a release. “The F&P Eson has been our best performing nasal mask and has proven extremely popular with both healthcare providers and patients. We believe with the large number of design improvements the F&P Eson 2 will be even more popular.”
F&P Eson 2 retains the same patented RollFit Seal technology as F&P Eson. RollFit automatically adjusts to effectively fit a wide variety of faces and aims to maintain a seal while minimizing the force applied to the bridge of the nose. The F&P Eson 2 includes intuitive headgear that has been redesigned for improved usability and fitting. VisiBlue highlights have been incorporated into key mask components to assist patients with mask orientation, use, and assembly. VisiBlue also assists providers to simplify instruction on equipment use and care.
“We put the patient and their needs at the center of our mask design and, like all of our masks, the F&P Eson 2 is designed to seal comfortably, simplify use, and improve treatment acceptability. Our innovative technologies have significantly advanced mask simplicity and performance, increasing the chance of long-term therapy success and, ultimately, improving patient care and outcomes,” says Gradon.
The F&P Eson 2 mask will initially be available in New Zealand and Australia from November, followed by Canada and Europe, and then the United States on receipt of US FDA clearance.